Concordia Healthcare to acquire IBS treatment Donnatal

Donnatal is Concordia Healthcare’s top offering, but Laurentian analyst Joseph Walewicz notes that no single product represents more than 10% of pro forma revenues.
>Concordia Healthcare (TSX:CXR) today announced that it would acquire Donnatal® for US$200 million in cash and shares that have a current market value of (U.S.) $65.3 million.

Privately held specialty pharmaceutical company Revive Pharmaceuticals (not to be confused with Revive Therapeutics Ltd. (TSXV: RVV), a clinical-stage company developing novel therapies for gout, sleep apnea and rare diseases) will continue to operate without the treatment.

Concordia CEO Mark Thompson explained the reasoning behind the pickup.

“The acquisition of Donnatal® represents an important advancement in the execution of Concordia’s legacy product strategy, providing substantial and sustainable revenue going forward,” he said. “In addition, we believe that Donnatal will have a significant and positive impact on Concordia’s net earnings and EBITDA.”

According to the National Institutes of Health, some 30% of Americans suffer from IBS at some time in their lives. The condition is second only to the common cold as a cause of absenteeism from work. IBS is one of the top 10 reasons for physician visits and the second most frequently encountered diagnosis in clinical practice, accounting for more physician visits than any symptoms other than those for respiratory tract infections.

At press time, shares of Concordia Healthcare were up 5.4% to $16.69.

Tagged with: cxr
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Why this fund manager loves Microsoft right now

Microsoft's (Microsoft Stock Quote, Chart, News, Analysts, Financials NASDAQ:MSFT) strong cash flow and balance sheet make it an attractive investment… [Read More]

3 hours ago

This Nova Scotia-based space company’s stock is a buy, analyst says

Growing demand for independent space launch facilities and increased defence spending could strengthen the outlook for Maritime Launch Services (Maritime… [Read More]

4 hours ago

Rubicon Organics disappoints: time to sell?

Rubicon Organics’ (Rubicon Organics Stock Quote, Chart, News, Analysts, Financials TSXV:ROMJ) slower-than-expected expansion of its Cascadia production facility has prompted… [Read More]

4 hours ago

Should you sell your Transat stock?

Persistently high fuel prices and growing pressure on Transat A.T.’s (Transat A.T. Stock Quote, Chart, News, Analysts, Financials TSX:TRZ) balance… [Read More]

15 hours ago

Analyst explains why Target may remain uncompetitive

Target’s (Target Corporation Stock Quote, Chart, News, Analysts, Financials NYSE:TGT) stronger-than-expected third-quarter results and improved earnings outlook have failed to… [Read More]

18 hours ago

Is Propel Holdings (TSX:PRL) undervalued?

Propel Holdings’ (Propel Holdings Stock Quote, Chart, News, Analysts, Financials TSX:PRL) expanding lending platform and use of artificial intelligence to… [Read More]

19 hours ago